Health Trials

Relapsed Or Refractory B Cell Lymphoma

4

Review clinical trials related to Relapsed Or Refractory B Cell Lymphoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma

This is a single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of pirtobrutinib as maintenance therapy in patients with relapsed or refractory B-cell lymphoma after commercial anti-CD19 CAR-T cell therapy.

Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Sun Yat-sen UniversityUpdated: Jun 3, 2026Locations: 1
Eligibility criteria

Able to understand and voluntarily sign the informed consent form. [+5]

History of other malignancies, except non-melanoma skin cancer without recurrenc... [+8]

Read more
Status: Recruiting

Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

To observe the efficacy and safety of a second infusion of relma-cel injection in patients with relapsed or refractory B-cell lymphoma.

Participants needed: 8
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Ruijin HospitalUpdated: Oct 23, 2024Locations: 1
Eligibility criteria

Patients have signed an Informed Consent Form (ICF). [+7]

Patients with hypersensitivity to active ingredients or any excipients (e.g., di... [+1]

Read more
Status: Not yet recruiting

Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL

To evaluate the efficacy and safety of selinexor combined with R-GDP regimen in the treatment of patients with TP53-altered relapsed or refractory B-cell lymphoma.

Participants needed: 50
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Ruijin HospitalUpdated: Nov 7, 2023Locations: 1
Eligibility criteria

Age≥18 [+7]

Prior treatment with selinexor or another XPO1 inhibitor [+12]

Read more
Status: Not yet recruiting

A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma

To evaluate the efficacy and safety of post-marketing Regiorense injection secondary infusion in the treatment of adult patients with relapsed or refractory B-cell lymphoma.

Participants needed: 13
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Changhai HospitalUpdated: Jun 15, 2023
Eligibility criteria

Informed Consent Form (ICF) was obtained from the patients. [+13]

Patients with hypersensitivity to the active ingredient or any excipients (dimet... [+1]

Read more